ISRG Stock Trading at its Cheapest in 10 Years: Should You Buy Now?

Intuitive Surgical (ISRG) trades at its lowest valuation in a decade, with a forward P/E of 30.26x, below its 10-year median. Despite a 40% decline, Q2 2026 revenue grew 19% to $2.89B, and EPS rose 28%. Management maintained 2026 da Vinci procedure growth forecast at 13.5-15.5%, citing international growth but noting U.S. and China uncertainties. ISRG's product pipeline includes da Vinci 5 and Ion systems, with innovations like SP procedures up 61%. Shares lag industry and sector, down 15% in 3

Original reporting
Published Sep 9, 2026, 1:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 6:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ISRG Stock Trading at its Cheapest in 10 Years: Should You Buy Now? — source image
Decision brief

The 30-second read

$ISRGNeutralMed
01

Why it matters

Earnings beat and guidance suggest continued growth, but valuation remains premium; investors must weigh cost pressures versus procedural growth.

02

Market read

The earnings update is material for traders tracking med‑tech valuations and could influence sector rotation.

03

What to watch

Potential upside from single‑port platform adoption and upcoming FDA clearance for a flexible robotic endoscope.

Relevance 7/10Novelty 6/10Timing: post‑quarter 2026 earnings release

Background

The article provides a valuation‑focused analysis of Intuitive Surgical after its Q2 2026 earnings release.

Company-level read

Ticker impact

$ISRGNeutralMedium confidence
Context

Q2 2026 results and updated guidance were disclosed for the first time, showing revenue up 19% YoY and adjusted EPS up 28% with a forward P/E of 30.26x.

Expected impact

Potential modest upside if the market re‑rates the valuation gap to peers.

Evidence & confidence

Earnings are solid and guidance is durable, yet valuation compression is limited by higher costs and competitive pressures.

Market effects

Highlights valuation disparity within the medical‑instruments sector, may prompt re‑rating of peers Medtronic and Stryker.

U.S. hospital spending outlook remains a key driver; Chinese tender volume uncertainty could affect broader med‑tech exposure.

Intuitive Surgical’s global footprint makes the earnings relevant to worldwide robotic‑surgery markets.

Counterpoint

Despite earnings beat, the stock may stay overvalued given high forward P/E and cost headwinds.

Key entities

  • Intuitive Surgical

    Manufacturer of da Vinci surgical robots.

Related articles

$ISRGMedAI 8/10

Intuitive Surgical Sinks 6% as U.S. da Vinci Growth Slows to “Lowest We’ve Seen Since COVID”

Intuitive Surgical (ISRG) shares dropped 6% after reporting Q3 revenue of $3.05B, adjusted EPS of $3.00, and U.S. da Vinci procedure growth of 10%, the lowest since COVID. The company narrowed its 2026 procedure growth outlook and took a $450M antitrust charge. Management plans to cut instrument and accessory revenue per procedure by 3%-5% to boost volume.

$ISRGMedAI 8/10

Intuitive’s US da Vinci procedure growth slows again

Intuitive Surgical reported Q3 revenue of $3.05B, up 22% YoY, with net income of $523M. U.S. da Vinci procedure growth slowed to 10%, the lowest since the pandemic. CEO David Rosa cited adoption challenges in benign general surgery. The company cut instrument prices to boost adoption in high-volume procedures, reducing near-term revenue per procedure. Intuitive adjusted its 2026 da Vinci procedure growth forecast to 14-15%.